HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.

Abstract
Thrombolytic treatment of ischemic stroke with tissue plasminogen activator (tPA) is markedly limited owing to concerns about hemorrhagic complications and the requirement that tPA be administered within 3 h of symptoms. Here we report that tPA activation of latent platelet-derived growth factor-CC (PDGF-CC) may explain these limitations. Intraventricular injection of tPA or active PDGF-CC, in the absence of ischemia, leads to significant increases in cerebrovascular permeability. In contrast, co-injection of neutralizing antibodies to PDGF-CC with tPA blocks this increased permeability, indicating that PDGF-CC is a downstream substrate of tPA within the neurovascular unit. These effects are mediated through activation of PDGF-alpha receptors (PDGFR-alpha) on perivascular astrocytes, and treatment of mice with the PDGFR-alpha antagonist imatinib after ischemic stroke reduces both cerebrovascular permeability and hemorrhagic complications associated with late administration of thrombolytic tPA. These data demonstrate that PDGF signaling regulates blood-brain barrier permeability and suggest potential new strategies for stroke treatment.
AuthorsEnming J Su, Linda Fredriksson, Melissa Geyer, Erika Folestad, Jacqueline Cale, Johanna Andrae, Yamei Gao, Kristian Pietras, Kris Mann, Manuel Yepes, Dudley K Strickland, Christer Betsholtz, Ulf Eriksson, Daniel A Lawrence
JournalNature medicine (Nat Med) Vol. 14 Issue 7 Pg. 731-7 (Jul 2008) ISSN: 1546-170X [Electronic] United States
PMID18568034 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzamides
  • Fibrinolytic Agents
  • Lymphokines
  • Piperazines
  • Platelet-Derived Growth Factor
  • Pyrimidines
  • platelet-derived growth factor C
  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor alpha
  • Tissue Plasminogen Activator
Topics
  • Animals
  • Benzamides
  • Blood-Brain Barrier (pathology)
  • Brain (blood supply, ultrastructure)
  • Brain Ischemia (metabolism, pathology)
  • Fibrinolytic Agents (metabolism)
  • Imatinib Mesylate
  • Lymphokines (metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Piperazines (pharmacology)
  • Platelet-Derived Growth Factor (metabolism)
  • Pyrimidines (pharmacology)
  • Receptor, Platelet-Derived Growth Factor alpha (antagonists & inhibitors)
  • Stroke (drug therapy)
  • Tissue Plasminogen Activator (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: